Alembic Clears FDA on Fingolimod, Pressing Into MS Generics

Alembic Pharmaceuticals has secured FDA final approval for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg, establishing a therapeutically equivalent generic to Novartis's Gilenya. For QA and regulatory teams at competing generics manufacturers, the approval signals that the ANDA pathway for this reference listed drug (RLD) has been successfully navigated, raising the competitive bar for others eyeing the same market.

Fingolimod is an established therapy in the multiple sclerosis space, and Gilenya Capsules, 0.5 mg, manufactured by Novartis Pharmaceuticals Corporation, serves as the RLD against which Alembic's submission was benchmarked. Achieving therapeutic equivalence designation under FDA's Orange Book standards requires demonstrated bioequivalence and full compliance with 21 CFR Part 211 current Good Manufacturing Practice requirements, a non-trivial regulatory burden for any applicant facility.

For plant heads and regulatory affairs leads at Indian generics manufacturers, Alembic's clearance reinforces a broader pattern: Indian-origin ANDAs continue to advance through FDA review in complex small-molecule categories. Facilities supporting similar submissions should expect heightened scrutiny of process validation packages and sterility assurance data, particularly where the RLD carries a narrow therapeutic index profile. Alignment with ICH Q10 pharmaceutical quality system principles will remain a baseline expectation for any facility seeking comparable approvals.

Source: Indian Pharma Post, reporting on an Alembic Pharmaceuticals announcement, published April 26, 2026. Pharma Now has not independently verified manufacturing site details beyond what is stated in the source.